<DOC>
	<DOCNO>NCT00313170</DOCNO>
	<brief_summary>This study ass relationship fulvestrant dose efficacy postmenopausal woman oestrogen receptor positive advanced breast cancer .</brief_summary>
	<brief_title>A Clinical Trial Compare Efficacy Tolerability Fulvestrant 250mg , 250mg Plus 250mg Loading Regimen 500mg</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Breast Cancer continue grow receive treatment antiestrogen hormonal treatment tamoxifen aromatase inhibitor . Requiring hormonal treatment . Postmenopausal woman ( woman stop menstrual period ) Treatment one previous regimen systemic anticancer therapy endocrine therapy advance BC . Treatment one previous regimen endocrine therapy advance BC . An exist condition prevents compliance .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>oncology</keyword>
	<keyword>cancer</keyword>
	<keyword>breast cancer</keyword>
</DOC>